RN
Cartesian Therapeutics, Inc.
RNAC · NASDAQ
$8.08 +0.25% (+$0.02)
1M -19.68%
Market Cap $237.4M
P/E Ratio -
Div. Yield -
ROE -
Piotroski F-Score Weak
2/9Valuation
0 /100
Expensive P/S 160.73x
EV/FFO N/A
P/E N/A
Growth
0 /100
Declining Rev. growth 70.66%
Book val. growth N/A
EPS growth N/A
Profitability
0 /100
Weak Op. margin 6,679.69%
Gross margin 766.42%
FCF margin 5,291.54%
Quality
0 /100
Poor Asset turnover 0.00x
ROIC 30.78%
ROA 48.31%
Debt
43 /100
Moderate Int. coverage -188.07x
Current ratio 7.48x
Debt/Assets N/A
Stability
26 /100
Unstable EPS volatility 1,029.74%
Beta 0.62x
Profitable years 0
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o RNAC
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Carsten Brunn
Employees
75
Headquarters
Frederick
Prihajajoči dogodki
05 NOV.
Earnings
Upcoming earnings report